Skip Navigation


NDT Advance Access originally published online on November 27, 2008
Nephrology Dialysis Transplantation 2009 24(2):673-675; doi:10.1093/ndt/gfn625
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
24/2/673    most recent
gfn625v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Winn, S. K.
Right arrow Articles by Marsh, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Winn, S. K.
Right arrow Articles by Marsh, J. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?

Simon K. Winn1, Sarah Ellis2, Philip Savage2, Stephen Sampson3 and James E. Marsh1

1 Department of Renal Medicine, St Helier Hospital, Carshalton, Surrey SM5 1AA 2 Department of Medical Oncology, Charing Cross Hospital, London W6 8RF 3 Department of Histopathology, St Helier Hospital, Carshalton, Surrey SM5 1AA, UK

Correspondence and offprint requests to: Simon K. Winn, Department of Renal Medicine, St Helier Hospital, Carshalton, Surrey SM5 1AA, UK. Tel: +0208-296-3698; +0208-644-8257; E-mail: simon.winn{at}epsom-sthelier.nhs.uk



  Abstract

Since their introduction in 2006, the tyrosine kinase inhibitors (TKI) Sunitinib and Sorafenib have become the standard of care for many patients with renal cancer. They are generally well tolerated and have not been significantly implicated in renal toxicity. We report the first biopsy confirmed occurrence of acute interstitial nephritis in a patient receiving treatment with Sunitinib for metastatic renal cell cancer. However, two previous descriptions of interstitial nephritis related to treatment with TKIs, combined with this current report suggest that TKI therapy could be associated with this rare but life-threatening complication.

Keywords: acute interstitial nephritis; renal cell carcinoma; sunitinib; tyrosine kinase inhibitors

Received for publication: 13.10.08
Accepted in revised form: 15.10.08


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
E. J. Rolleman, J. Weening, and M. G. H. Betjes
Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma
Nephrol. Dial. Transplant., June 1, 2009; 24(6): 2002 - 2003.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.